Wirtz Heidi S, Calip Gregory S, Buist Diana S M, Gralow Julie R, Barlow William E, Gray Shelly, Boudreau Denise M
Am J Epidemiol. 2017 Apr 15;185(8):661-672. doi: 10.1093/aje/kww242.
In previous studies, we found modestly decreased and increased risks of second breast cancer events with the use of statins and antibiotics, respectively, after adjustment for surveillance mammography. We evaluated detection bias by comparing receipt of surveillance mammography among users of these 2 disparate classes of medication. Adult women diagnosed with early-stage breast cancer during 1990-2008 (n = 3,965) while enrolled in an integrated health-care plan (Group Health Cooperative; Washington State) were followed for up to 10 years in the Commonly Used Medications and Breast Cancer Outcomes (COMBO) Study. Categories of antibiotic use included infrequent (1-3 dispensings/12 months) and frequent (≥4 dispensings/12 months) use, and categories of statin use included less adherent (1 dispensing/6 months) and adherent (≥2 dispensings/6 months). We examined associations between medication use and surveillance mammography using multivariable generalized estimating equations and evaluated the impact of adjusting for surveillance within Cox proportional hazard models. Frequent antibiotic users were less likely to receive surveillance mammography (odds ratio (OR) = 0.90, 95% confidence interval (CI): 0.82, 0.99) than were nonusers; no association was found among infrequent users (OR = 0.96, 95% CI: 0.90, 1.03). Adherent statin use was associated with more surveillance compared with nonuse (OR = 1.11, 95% CI: 1.01, 1.25), but less adherent statin use was not (OR = 1.03, 95% CI: 0.81, 1.31). No difference in associations between medications of interest and second breast cancer events was observed when surveillance was removed from otherwise adjusted models. The influence of detection bias by medication use warrants further exploration.
在之前的研究中,我们发现,在对乳腺钼靶筛查进行校正后,使用他汀类药物和抗生素分别使二次乳腺癌事件的风险适度降低和升高。我们通过比较这两类不同药物使用者接受乳腺钼靶筛查的情况来评估检测偏倚。在常用药物与乳腺癌结局(COMBO)研究中,对1990年至2008年期间确诊为早期乳腺癌的成年女性(n = 3965)进行了长达10年的随访,这些女性均加入了一项综合医疗保健计划(Group Health Cooperative;华盛顿州)。抗生素使用类别包括不频繁使用(1 - 3次配药/12个月)和频繁使用(≥4次配药/12个月),他汀类药物使用类别包括依从性较差(1次配药/6个月)和依从性较好(≥2次配药/6个月)。我们使用多变量广义估计方程研究了药物使用与乳腺钼靶筛查之间的关联,并在Cox比例风险模型中评估了校正筛查后的影响。与未使用者相比,频繁使用抗生素的人接受乳腺钼靶筛查的可能性较小(优势比(OR)= 0.90,95%置信区间(CI):0.82,0.99);在不频繁使用者中未发现关联(OR = 0.96,95% CI:0.90,1.03)。与未使用他汀类药物相比,依从性较好的他汀类药物使用与更多的筛查相关(OR = 1.11,95% CI:1.01,1.25),但依从性较差的他汀类药物使用则不然(OR = 1.03,95% CI:0.81,1.31)。当从其他校正模型中去除筛查因素时,未观察到感兴趣的药物与二次乳腺癌事件之间的关联存在差异。药物使用导致的检测偏倚的影响值得进一步探讨。